Icosagen is a unique European CRDMO, being successfully in the business for more than 26 years as an independent family-owned company. As such, we combine pre-clinical CRO and clinical CDMO development expertise at one single site for therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates. As a CRDMO we discover, develop, and manufacture proteins seamlessly from research concepts into pre-clinical and clinical development stages. This includes everything from small-scale transient productions to stable high producing cell lines, to manufacture clinical GMP materials in our modern 200/1000L GMP facility.
Looking for a particular Icosagen Group employee's phone or email?
The Icosagen Group annual revenue was $3 million in 2026.
Mart Ustav is the CEO of Icosagen Group.
98 people are employed at Icosagen Group.
The NAICS codes for Icosagen Group are [5417, 541, 541713, 54171, 54].
The SIC codes for Icosagen Group are [87, 873].